Albany Molecular Research (AMRI) Tops Q2 EPS by 4c; Updates FY16 Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AMRI Announces Second Quarter 2016 Results
August 4, 2016 7:31 AM EDTALBANY, N.Y., Aug. 4, 2016 /PRNewswire/ --Â AMRI (NASDAQ: AMRI) today reported financial and operating results for the second quarter ended June 30, 2016 and provided an update to its outlook for 2016.
Highlights:
Contract revenue of $116.5 million, up 37% from the second quarter 2015 Recurring royalty revenue of $4.4 million Reported contract margins of 29%; non-GAAP contract margins of 33% Reported net loss of ($21.3) million; non-GAAP net income of $12.7 million Reported diluted EPS $(0.61); non-GAAP diluted EPS of $0.36 Adjusted EBITDA of $26.8 million, up 62% from the second quarter 2015 Updates... More